Research programme: viral infection vaccines - Protein Potential
Latest Information Update: 28 Aug 2020
At a glance
- Originator Protein Potential
- Class Dengue vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dengue; Severe acute respiratory syndrome
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Dengue(Prevention) in USA (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Severe acute respiratory syndrome(Prevention) in USA (Parenteral)
- 19 Jul 2016 Preclinical trials in Dengue (Prevention) in USA (Parenteral)
Development Overview
Introduction
Protein Potential is developing vaccines for the prevention of viral infections, including SARS (Severe Acute Respiratory Syndrome) and dengue fever. Development is at preclinical stage in the US.
As at August 2020, no recent reports of development had been identified for preclinical development in Dengue (Prevention) in USA (Parenteral), preclinical development in Severe acute respiratory syndrome (Prevention) in USA (Parenteral).
Key Development Milestones
Protein Potential is developing vaccines for the prevention of SARS and dengue fever in preclinical studies in the US.
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Dengue vaccines, Viral vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B-X (Other viral vaccines)
-
EPhMRA code
J7A9 (Other specified single component)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Dengue | - | Prevention | No development reported (Preclinical) | USA | Parenteral / unspecified | Protein Potential | 28 Aug 2020 |
| Severe acute respiratory syndrome | - | Prevention | No development reported (Preclinical) | USA | Parenteral / unspecified | Protein Potential | 28 Aug 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Protein Potential | Originator | USA |
| Protein Potential | Owner | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Aug 2020 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Dengue(Prevention) in USA (Parenteral) Updated 28 Aug 2020 |
| 28 Aug 2020 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Severe acute respiratory syndrome(Prevention) in USA (Parenteral) Updated 28 Aug 2020 |
| 19 Jul 2016 | Phase Change - Preclinical | Preclinical trials in Dengue (Prevention) in USA (Parenteral) Updated 19 Jul 2016 |
| 19 Jul 2016 | Phase Change - Preclinical | Preclinical trials in Severe acute respiratory syndrome (Prevention) in USA (Parenteral) Updated 19 Jul 2016 |
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG